Jazz Pharmaceuticals Public (Nasdaq: JAZZ ) is expected to report Q4 earnings on Feb. 26. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Jazz Pharmaceuticals Public's revenues will increase 122.0% and EPS will grow 56.7%.
The average estimate for revenue is $185.4 million. On the bottom line, the average EPS estimate is $1.41.
Last quarter, Jazz Pharmaceuticals Public reported revenue of $175.5 million. GAAP reported sales were much higher than the prior-year quarter's $73.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.34. GAAP EPS of $0.55 for Q3 were 20% lower than the prior-year quarter's $0.69 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 87.3%, 740 basis points worse than the prior-year quarter. Operating margin was 39.7%, 1,440 basis points worse than the prior-year quarter. Net margin was 18.9%, 2,540 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $592.4 million. The average EPS estimate is $4.59.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 213 members out of 279 rating the stock outperform, and 66 members rating it underperform. Among 75 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 57 give Jazz Pharmaceuticals Public a green thumbs-up, and 18 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $64.33.